Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous Siponimod: A Randomized, Open-label Study in Healthy Subjects.

Shakeri-Nejad K, Gardin A, Gray C, Neelakantham S, Dumitras S, Legangneux E.

Clin Ther. 2020 Jan;42(1):175-195. doi: 10.1016/j.clinthera.2019.11.014. Epub 2020 Jan 8.

2.

Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.

Gardin A, Shakeri-Nejad K, Feller A, Huth F, Neelakantham S, Dumitras S.

Eur J Clin Pharmacol. 2019 Nov;75(11):1565-1574. doi: 10.1007/s00228-019-02729-7. Epub 2019 Aug 7.

PMID:
31392364
3.

Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects.

Gardin A, Gray C, Neelakantham S, Huth F, Davidson AM, Dumitras S, Legangneux E, Shakeri-Nejad K.

Eur J Clin Pharmacol. 2018 Dec;74(12):1593-1604. doi: 10.1007/s00228-018-2533-2. Epub 2018 Aug 13.

PMID:
30105453
4.

Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects.

Gardin A, Ufer M, Legangneux E, Rossato G, Jin Y, Su Z, Pal P, Li W, Shakeri-Nejad K.

Clin Pharmacokinet. 2019 Mar;58(3):349-361. doi: 10.1007/s40262-018-0700-3.

5.

Impact of siponimod on vaccination response in a randomized, placebo-controlled study.

Ufer M, Shakeri-Nejad K, Gardin A, Su Z, Paule I, Marbury TC, Legangneux E.

Neurol Neuroimmunol Neuroinflamm. 2017 Sep 13;4(6):e398. doi: 10.1212/NXI.0000000000000398. eCollection 2017 Nov.

6.

Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study
.

Gardin A, Dodman A, Kalluri S, Neelakantham S, Tan X, Legangneux E, Shakeri-Nejad K.

Int J Clin Pharmacol Ther. 2017 Jan;55(1):54-65. doi: 10.5414/CP202608.

PMID:
27841151
7.

Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study
.

Shakeri-Nejad K, Aslanis V, Veldandi UK, Gardin A, Zaehringer A, Dodman A, Su Z, Legangneux E.

Int J Clin Pharmacol Ther. 2017 Jan;55(1):41-53. doi: 10.5414/CP202588.

PMID:
27443658
8.

Cardiac Effects of Siponimod (BAF312) Re-initiation After Variable Periods of Drug Discontinuation in Healthy Subjects.

Legangneux E, Shakeri-Nejad K, Aslanis V, Sagkriotis A, Pezous N, Brendani B, Behrje R, Gutierrez M.

Clin Ther. 2016 Mar;38(3):631-45.e1. doi: 10.1016/j.clinthera.2016.01.021. Epub 2016 Feb 23.

PMID:
26916566
9.

Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.

Shakeri-Nejad K, Aslanis V, Veldandi UK, Mooney L, Pezous N, Brendani B, Juan A, Allison M, Perry R, Legangneux E.

Clin Ther. 2015 Nov 1;37(11):2489-2505.e2. doi: 10.1016/j.clinthera.2015.09.006. Epub 2015 Oct 27.

PMID:
26519230
10.

AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation.

Feuerbach D, Pezous N, Weiss M, Shakeri-Nejad K, Lingenhoehl K, Hoyer D, Hurth K, Bilbe G, Pryce CR, McAllister K, Chaperon F, Kucher K, Johns D, Blaettler T, Lopez Lopez C.

Br J Pharmacol. 2015 Mar;172(5):1292-304. doi: 10.1111/bph.13001. Epub 2015 Jan 12.

11.

Efficacy and safety of the dual L- and T-type calcium channel blocker, ACT-280778: a proof-of-concept study in patients with mild-to-moderate essential hypertension.

Dingemanse J, Otasevic P, Shakeri-Nejad K, Klainman E, Putnikovic B, Kracker H, Mueller MS, Zimlichman R.

J Hum Hypertens. 2015 Apr;29(4):229-35. doi: 10.1038/jhh.2014.79. Epub 2014 Sep 18.

PMID:
25231512
12.

Tolerability and pharmacokinetics of ACT-280778, a novel nondihydropyridine dual L/T-type calcium channel blocker: early clinical studies in healthy male subjects using adaptive designs.

Mueller MS, Shakeri-Nejad K, Gutierrez MM, Krause A, Täubel J, Sanderson B, Dingemanse J.

J Cardiovasc Pharmacol. 2014 Feb;63(2):120-31. doi: 10.1097/FJC.0000000000000030.

PMID:
24126567
13.

Influence of mild and moderate liver impairment on the pharmacokinetics and metabolism of almorexant, a dual orexin receptor antagonist.

Shakeri-Nejad K, Hoch M, Hoever P, Dingemanse J.

Eur J Pharm Sci. 2013 Aug 16;49(5):836-44. doi: 10.1016/j.ejps.2013.06.002. Epub 2013 Jun 11.

PMID:
23770377
14.

Elucidation of the metabolic pathways and the resulting multiple metabolites of almorexant, a dual orexin receptor antagonist, in humans.

Dingemanse J, Hoever P, Hoch M, Treiber A, Wagner-Redeker W, Miraval T, Hopfgartner G, Shakeri-Nejad K.

Drug Metab Dispos. 2013 May;41(5):1046-59. doi: 10.1124/dmd.112.050120. Epub 2013 Feb 21.

PMID:
23431113
15.

Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.

Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K.

J Clin Pharmacol. 2008 Dec;48(12):1411-9. doi: 10.1177/0091270008324179. Epub 2008 Sep 30.

PMID:
18827075
16.

Drug interactions during therapy with three major groups of antimicrobial agents.

Shakeri-Nejad K, Stahlmann R.

Expert Opin Pharmacother. 2006 Apr;7(6):639-51. Review.

PMID:
16556082

Supplemental Content

Loading ...
Support Center